<DOC>
	<DOCNO>NCT02596217</DOCNO>
	<brief_summary>Safety , tolerability pharmacokinetics single dose BI 655066/ABBV-066 ( risankizumab ) healthy Chinese , Japanese Caucasian male volunteer .</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetics BI 655066/ABBV-066 ( Risankizumab ) Healthy Asian Caucasian Male Volunteers</brief_title>
	<detailed_description />
	<criteria>Inclusion criterion : 1 . Healthy male subject accord investigatorÂ¿s assessment , base complete medical history include physical examination , vital sign ( BP , PR ) , 12lead ECG , clinical laboratory test 2 . Chinese ethnicity , Japanese ethnicity , Caucasian accord follow criterion : Chinese ; bear China ethnic Chinese born outside China , descendent 4 ethnic Chinese grandparent born china Japanese ; bear Japan , live outside Japan &lt; 10 year , parent grandparent born Japan Caucasian 3 . Age 20 45 year ( incl . ) 4 . BMI 18.5 25 kg/m2 ( incl . ) Chinese Japanese subject , BMI 18.5 29.9 kg/m2 ( incl . ) Caucasian subject . 5 . Signed date write informed consent prior admission study accordance GCP local legislation . 6 . Male subject agree minimize risk female partner become pregnant fulfilling follow criterion start least 30 day first administration trial medication 30 day trial completion : Use adequate contraception , e.g . follow method plus condom : implant , combine oral vaginal contraceptive , intrauterine device Sexually abstinent Vasectomised ( vasectomy least 1 year prior enrolment ) Surgically sterilise ( include hysterectomy ) Exclusion criterion : 1 . Any finding medical examination ( include BP , PR ECG ) deviate normal judge clinically relevant investigator 2 . Any laboratory value outside reference range investigator considers clinical relevance 3 . Any evidence concomitant disease judge clinically relevant investigator 4 . Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder 5 . Surgery gastrointestinal tract could interfere kinetics trial medication ( except appendectomy simple hernia repair ) 6 . Diseases central nervous system ( include limit kind seizure stroke ) , relevant neurological psychiatric disorder 7 . History relevant orthostatic hypotension , faint spell , blackouts 8 . Chronic relevant acute infection include HIV , viral hepatitis ( ) tuberculosis evidence tuberculosis infection define positive QuantiFERON TBGold ( TSPOT ) test . Subjects positive QuantiFERON TBGold ( TSPOT ) test may participate study work ( accord local practice/guidelines ) establish conclusively subject evidence active tuberculosis . If presence latent tuberculosis establish , treatment must initiate maintain accord local country guideline . 9 . History relevant allergy hypersensitivity ( include allergy trial medication excipients ) 10 . Intake biologic agent current study medication drug consider likely interfere safe conduct study 11 . Intake drug long halflife ( 24 h ) within 30 day less 10 halflives respective drug prior administration trial medication 12 . Within 10 day prior administration trial medication , use drug might reasonably influence result trial might prolong QT/QTc interval 13 . Participation another trial investigational drug within 90 day 5 halflives ( whichever great ) prior plan administration trial medication 14 . Smoker ( 10 cigarette 3 cigar 3 pipe per day ) 15 . Inability refrain smoke specify trial day 16 . Alcohol abuse ( consumption 30 g per day ) 17 . Drug abuse positive drug screen 18 . Blood donation 100 mL within 30 day prior administration trial medication intend donation trial 19 . Intention perform excessive physical activity within one week prior administration trial medication trial 20 . Inability comply dietary regimen trial site 21 . A marked baseline prolongation QT/QTc interval ( QTc interval repeatedly great 450 m ) relevant ECG find screen 22 . A history additional risk factor Torsades de Pointes ( heart failure , hypokalemia , family history Long QT Syndrome ) 23 . Have receive live bacterial live viral vaccination 12 week prior date screening . Subjects must agree receive live bacterial live viral vaccination study 12 month last administration study drug 24 . Have receive Bacille CalmetteGuerin ( BCG ) vaccination 12 month prior date screening . Subjects must agree receive BCG vaccination study 12 month last administration study drug 25 . Subject assess unsuitable inclusion investigator , instance , consider able understand comply study requirement , condition would allow safe participation study</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>ABBV-066</keyword>
	<keyword>BI 655066</keyword>
	<keyword>risankizumab</keyword>
</DOC>